{"id":"W2982040065","doi":"10.1016/j.jtho.2019.08.424","title":"OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Ipilimumab; Cohort; Internal medicine; Nivolumab; Discontinuation; Oncology; Adverse effect; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003761288,0.0002861859,0.0007572724,0.0002597844,0.0002764129,0.0007637092,0.0003330044,0.0004561206,0.00445422],"category_scores_gemma":[0.0009626866,0.0001912354,0.0008468606,0.0003013538,0.0001780084,0.0004924933,0.0002472074,0.0009190163,0.0006784784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007310205,"about_ca_system_score_gemma":0.0009425234,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001831597,"about_ca_topic_score_gemma":0.007054347,"domain_scores_codex":[0.9998226,0.00004205294,0.00001492604,0.00004446537,0.00002484218,0.00005123822],"domain_scores_gemma":[0.9997038,0.00006161339,0.00005671617,0.00001438154,0.00002508235,0.0001384535],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.155526,0.002949641,0.3585997,0.001393471,0.002867502,0.001014115,0.0001856816,0.002581907,0.01526543,0.000663404,0.02886933,0.4300838],"study_design_scores_gemma":[0.05117172,0.06894279,0.80346,0.0008040864,0.006440411,0.00389461,0.0003743153,0.008004523,0.006095001,0.001235282,0.04943254,0.0001446265],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9796282,0.009538699,0.0002213343,0.001105423,0.0004409396,0.0001779767,0.00136836,0.00009156426,0.007427447],"genre_scores_gemma":[0.9930478,0.001950784,0.0003324338,0.0009560894,0.0001871796,0.00008452258,0.001783871,0.00001637077,0.001641035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00445422,"threshold_uncertainty_score":0.01490086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01503708710134724,"score_gpt":0.3432745938222109,"score_spread":0.3282375067208637,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}